Double Duty: Creating Trials To Satisfy Both FDA And CMS
This article was originally published in The Gray Sheet
Executive Summary
Firms can do "double duty" by gathering economic data during their FDA pivotal trials to get a jump start on CMS coverage, according to Abbott Diagnostic's Barbara Calvert, director of medical products reimbursement
You may also be interested in...
Reimbursement Is More Than Passing Thought For Spine Firm In FDA Trials
Non-fusion spinal implant maker Paradigm Spine decided to spend 15%-20% more than needed to satisfy FDA's data requirements in an ongoing pivotal trial for what the company hopes will be its first product on the U.S. market
Reimbursement Is More Than Passing Thought For Spine Firm In FDA Trials
Non-fusion spinal implant maker Paradigm Spine decided to spend 15%-20% more than needed to satisfy FDA's data requirements in an ongoing pivotal trial for what the company hopes will be its first product on the U.S. market
Critical Path To Payment? Venture Capitalists Seek Medicare Refocus
The National Venture Capital Association is lobbying CMS to make better use of its Council on Technology & Innovations to streamline and standardize the reimbursement process for novel technologies